P1.062. Discovery of Novel Dual-Target Inhibitors for EGFR and PIK3CA From Natural Products via Machine Learning and Molecular Simulation

Clicks: 18
ID: 326011
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #265 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Molecular Biology/Pathology Background With the advancement of personalized medicine, multi-target drug development has garnered significant attention, particularly for complex diseases such as cancer. This study aims to identify potential dual-target inhibitors against Epidermal Growth Factor Receptor (EGFR) and Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), two proteins whose aberrant activation is closely associated with tumorigenesis and progression in various cancers. Methods We collected IC50 values of active compounds for EGFR and PIK3CA from the BindingDB database, which were then standardized to pIC50 values using RDKit. A total of 2048 Extended-Connectivity Fingerprints (ECFPs) were calculated to serve as molecular descriptors. Various machine learning models, including Support Vector Machine (SVM), Decision Tree, Random Forest, Gradient Boosting, K-Nearest Neighbors, and LightGBM, were developed. The optimal model parameters were determined using ten-fold cross-validation and grid search, and model performance was assessed by Mean Absolute Error (MAE), Mean Squared Error (MSE), and the R-squared (R2) value. Results The SVM model demonstrated the best performance and was selected to predict activities for both EGFR and PIK3CA. Conclusion The natural product compounds CNP0456830 and CNP0467494 exhibited the lowest binding free energies for both EGFR and PIK3CA, identifying them as the most promising dual-target inhibitors. This study offers a new direction and a potential therapeutic strategy for personalized drug design in cancer treatment.
Reference Key
openalex_W7203965783 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Simiao Lu, Yi Zhu, Yongtao Han, Qiuling Shi, Xuefeng Leng
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.210
URL
https://doi.org/10.1093/dote/doag077.210
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.